GYPA and acute lymphoblastic leukemia: On diagnosis baseline and throughout induction therapy (D0, D15 and D35) in the B-ALL PB group, there was a consistent predominance of EV-CD235a+ and EV-CD51/61+ in the sEV and mEV size ranges.